Rapid growth of Merkel cell carcinoma after treatment with rituximab

J Drugs Dermatol. 2006 Feb;5(2):180-1.

Abstract

Merkel cell carcinoma is an uncommon neuroendocrine carcinoma of the skin. We report a case of rapid growth of Merkel cell carcinoma after treatment with rituximab, a new anti-CD20 monoclonal antibody, for acquired factor VIII inhibitor. We propose that rituximab may place patients at higher risk for aggressive Merkel cell carcinoma thus necessitating the need for increased long-term surveillance of these patients.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Merkel Cell / pathology*
  • Female
  • Humans
  • Rituximab
  • Skin Neoplasms / pathology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab